Rapid Micro Biosystems Analyst Ratings
Rapid Micro Biosystems Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/11/2022 | 108.88% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 03/07/2022 | 161.1% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 02/15/2022 | 187.21% | Morgan Stanley | $24 → $11 | Maintains | Equal-Weight |
| 11/15/2021 | 526.63% | Morgan Stanley | $26 → $24 | Maintains | Equal-Weight |
| 08/09/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/09/2021 | 578.85% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 08/09/2021 | 631.07% | Stifel | → $28 | Initiates Coverage On | → Buy |
| 08/09/2021 | 683.29% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/16/2022 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 05/11/2022 | 108.88% | 摩根士丹利 | 10 美元 → 8 美元 | 維持 | 等重 |
| 03/07/2022 | 161.1% | 摩根士丹利 | 11 美元 → 10 美元 | 維持 | 等重 |
| 2022 年 2 月 15 日 | 187.21% | 摩根士丹利 | 24 美元 → 11 美元 | 維持 | 等重 |
| 11/15/2021 | 526.63% | 摩根士丹利 | 26 美元 → 24 美元 | 維持 | 等重 |
| 2021 年 9 月 8 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2021 年 9 月 8 日 | 578.85% | 摩根士丹利 | → 26 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 2021 年 9 月 8 日 | 631.07% | Stifel | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 9 月 8 日 | 683.29% | 摩根大通 | → 30 美元 | 啓動覆蓋範圍開啓 | → 超重 |
Rapid Micro Biosystems Questions & Answers
快速微生物系統問題與解答
The latest price target for Rapid Micro Biosystems (NASDAQ: RPID) was reported by JP Morgan on August 16, 2022. The analyst firm set a price target for $0.00 expecting RPID to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
摩根大通於2022年8月16日公佈了快速微生物系統公司（納斯達克股票代碼：RPID）的最新目標股價。該分析公司將目標股價設定爲0.00美元，預計RPID將降至12個月內（可能下跌-100.00％）。去年有5家分析公司公佈了評級。
The latest analyst rating for Rapid Micro Biosystems (NASDAQ: RPID) was provided by JP Morgan, and Rapid Micro Biosystems downgraded their neutral rating.
Rapid Micro Biosystems（納斯達克股票代碼：RPID）的最新分析師評級由摩根大通提供，快速微生物系統下調了中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rapid Micro Biosystems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rapid Micro Biosystems was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Rapid Micro Biosystems的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Rapid Micro Biosystems的最後一次評級是在2022年8月16日提交的，因此您應該預計下一個評級將在2023年8月16日左右公佈。
While ratings are subjective and will change, the latest Rapid Micro Biosystems (RPID) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rapid Micro Biosystems (RPID) is trading at is $3.83, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的快速微生物系統（RPID）評級下調，目標股價爲0.00美元至0.00美元。快速微生物系統（RPID）當前的交易價格爲3.83美元，超出了分析師的預測區間。